Given the links between activating GC-C mutations and IBD in humans, as well as the supporting evidence from transgenic mice of GC-C activation, we cannot rule out that downregulation of GC-C and its ligands in IBD patients and in a mouse model of experimental colitis could be an adaptive mechanism of epithelial preservation (10, 13, 16). Here, GUCY2C is linked to inflammatory bowel disease.